scholarly journals Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions

2020 ◽  
Vol 6 (1) ◽  
pp. 9-23
Author(s):  
Kyle B. Zuniga ◽  
Rebecca E. Graff ◽  
David B. Feiger ◽  
Maxwell V. Meng ◽  
Sima P. Porten ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Future Directions ◽  
Muscle Invasive ◽  
Bladder Cancer Recurrence

scholarly journals Deceptive Muscle Invasive Bladder Cancer Recurrence With Benign Biopsy Foci After Bladder Sparing Treatment

Medicine ◽  
2015 ◽  
Vol 94 (22) ◽  
pp. e898 ◽  
Author(s):  
Chuanliang Xu ◽  
Shuxiong Zeng ◽  
Zhensheng Zhang ◽  
Ruixiang Song ◽  
Chong Ma ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Bladder Sparing ◽  
Bladder Cancer Recurrence ◽  
Benign Biopsy

Therapy for Non-Muscle Invasive Bladder Cancer: HP-NAP

2012 ◽  
Vol 79 (2) ◽  
pp. 142-148 ◽  
Author(s):  
Daniele D'Agostino ◽  
Marco Racioppi ◽  
Alessio Filianoti ◽  
Luca Di Gianfrancesco ◽  
Gaia Codolo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
New Drugs ◽  
In Vivo Studies ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Ifn Γ ◽  
Muscle Invasive ◽  
Bladder Cancer Recurrence

Purpose Patients with non-muscle invasive bladder cancer recurrence after 2 induction courses of BCG are eligible for radical cystectomy. So, in the last years research to discover new drugs for the management of non-muscle invasive bladder cancer recurrence after failure of first and second line therapy is ongoing. In accordance to the results obtained with BCG, whose mechanism depends on the induction of the T helper 1 (TH1) immune response, we investigated the activity of a Toll-like receptor (TLR) 2 ligand, named Helicobacter Pylori Neutrophil Activating Protein (HP-NAP), that we recently demonstrated being able of enhancing the differentiation of Th1 cells, both in vitro and in vivo, because of its ability to create an IL-12 enriched milieu. Materials and Methods We show here, in a mouse model of bladder neoplasm implants, that local administration of HP-NAP decreases tumor growth by inducing tumor necrosis. Results The result is joined up with a massive cluster of both CD4+ and CD8+ IFN-γ+ cells, within neoplasm and regional lymph nodes. It is of note that HP-NAP-treated tumors show also a reduced vascularization due to the anti-angiogenic activity of IFN-γ induced by HP-NAP. Conclusions The present study suggests that the activity of HP-NAP against urothelial tumor burden warrants subsequent in vivo studies.

Sign in / Sign up

Export Citation Format

Share Document